WO2008079963A3 - Pharmaceutical compositions comprising ionic complexes of active pharmaceutical ingredients - Google Patents

Pharmaceutical compositions comprising ionic complexes of active pharmaceutical ingredients Download PDF

Info

Publication number
WO2008079963A3
WO2008079963A3 PCT/US2007/088354 US2007088354W WO2008079963A3 WO 2008079963 A3 WO2008079963 A3 WO 2008079963A3 US 2007088354 W US2007088354 W US 2007088354W WO 2008079963 A3 WO2008079963 A3 WO 2008079963A3
Authority
WO
WIPO (PCT)
Prior art keywords
ionic complexes
apis
pharmaceutical compositions
ingredients
pharmaceutical
Prior art date
Application number
PCT/US2007/088354
Other languages
French (fr)
Other versions
WO2008079963A2 (en
Inventor
Erik T Michalson
Brian T Becicka
Paul A Jass
Rachel N Catherman
Original Assignee
Cambrex Charles City Inc
Erik T Michalson
Brian T Becicka
Paul A Jass
Rachel N Catherman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambrex Charles City Inc, Erik T Michalson, Brian T Becicka, Paul A Jass, Rachel N Catherman filed Critical Cambrex Charles City Inc
Publication of WO2008079963A2 publication Critical patent/WO2008079963A2/en
Publication of WO2008079963A3 publication Critical patent/WO2008079963A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to pharmaceutical compositions comprising ionic complexes of anion-containing APIs as new chemical entities. Such ionic complexes of the anion-containing APIs have utility for preparing oral delivery forms of the respective APIs. The invention further provides methods for the preparation and oral delivery of ionic complexes of APIs having an amine functionality.
PCT/US2007/088354 2006-12-22 2007-12-20 Pharmaceutical compositions comprising ionic complexes of active pharmaceutical ingredients WO2008079963A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87147606P 2006-12-22 2006-12-22
US60/871,476 2006-12-22

Publications (2)

Publication Number Publication Date
WO2008079963A2 WO2008079963A2 (en) 2008-07-03
WO2008079963A3 true WO2008079963A3 (en) 2008-11-06

Family

ID=39563207

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/088354 WO2008079963A2 (en) 2006-12-22 2007-12-20 Pharmaceutical compositions comprising ionic complexes of active pharmaceutical ingredients

Country Status (1)

Country Link
WO (1) WO2008079963A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8920838B2 (en) 2006-08-03 2014-12-30 Horizon Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012010170A2 (en) 2009-10-28 2016-04-12 Mcneil Ppc Inc fast disintegrating / dissolving coating compositions
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
CN105640907B (en) * 2016-01-26 2018-04-17 北京金阳利康医药有限公司 Cefdinir dispersible tablet and preparation method thereof
EP3251661B1 (en) * 2016-05-30 2020-12-23 Sun Pharmaceutical Industries Limited Raloxifene sprinkle composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096791A1 (en) * 2001-05-31 2003-05-22 Cima Labs Inc. Taste masking of highly water-soluble drugs
US6806256B2 (en) * 2001-03-05 2004-10-19 Ortho -Mcneil Pharmaceutical, Inc. Taste masked liquid pharmaceutical compositions
US20060127472A1 (en) * 2004-12-13 2006-06-15 Keith Whitehead Taste-masked prednisolone oral formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6806256B2 (en) * 2001-03-05 2004-10-19 Ortho -Mcneil Pharmaceutical, Inc. Taste masked liquid pharmaceutical compositions
US20030096791A1 (en) * 2001-05-31 2003-05-22 Cima Labs Inc. Taste masking of highly water-soluble drugs
US20060127472A1 (en) * 2004-12-13 2006-06-15 Keith Whitehead Taste-masked prednisolone oral formulations

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8920838B2 (en) 2006-08-03 2014-12-30 Horizon Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
US9504699B2 (en) 2006-08-03 2016-11-29 Hznp Limited Delayed-release glucocorticoid treatment of rheumatoid disease

Also Published As

Publication number Publication date
WO2008079963A2 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
EP3626253A3 (en) Stable formulations of linaclotide
SG150075A1 (en) Particles for delivery of active ingredients, process of making and compositions thereof
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
NZ602557A (en) Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
WO2006010423A3 (en) Azaindole inhibitors of mtp and apob
WO2009055568A3 (en) Liposomal vancomycin formulations
MY143795A (en) Tetrahydropyridoindole derivatives
UA98804C2 (en) Catecholamine derivatives and pharmaceutical composition based thereon
JO2973B1 (en) Fumarate Salt Of (alphaS, betaR)-6-Bromo-alfa-[2-(dimethylamino)ethyl]-2- Methoxy-alpha-1-naphthalenyl-beta-phenyl-3- Quinolineethanol
MX358716B (en) Oral care product and methods of use and manufacture thereof.
WO2007102127A3 (en) New amines
WO2009130616A3 (en) Improved tlr3 agonist compositions
WO2012058675A3 (en) Zinc oxide complexes
WO2007146293A3 (en) Improved composition and method for taste masking
WO2011051968A3 (en) Pharmaceutical compositions of lanthanum carbonate and process for the preparation thereof
WO2008079963A3 (en) Pharmaceutical compositions comprising ionic complexes of active pharmaceutical ingredients
WO2009032843A3 (en) Deuterated ethambutols and their use
WO2007087026A3 (en) Solid-state form of amg 706 and pharmaceutical compositions thereof
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
WO2011056785A3 (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
UA103996C2 (en) Ivabradine hydrobromide
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07865919

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07865919

Country of ref document: EP

Kind code of ref document: A2